US-based developer Baxter International has entered new licensing agreements with Israel’s Tel Aviv University (TAU) and Tel Aviv Sourasky Medical Centre (TASMC) to aid the development of new technologies for surgical care.
Collaborated through TAU’s business engagement arm, Ramot, the agreements include global joint research to assess various technologies being developed at the university and TASMC.
Under the first agreement, Baxter will exclusively licence the TAU Technology Innovation Momentum Fund technology, while it will licence TAU and TASMC technology for use in potential applications from the joint research as part of a second agreement.
Baxter Advanced Surgery president Wil Boren said: “Baxter is committed to finding creative pathways to bring innovative solutions to the operating room.
“By working with leading experts at TAU and TASMC, we have access to promising early-stage research that could have a meaningful impact for surgeons looking for new tools to treat complex cases.”
Expected to expand and support Baxter’s existing portfolio of products, the joint projects intend to target large and unmet needs for surgical care.
The firm’s portfolio currently includes renal and hospital products such as home, acute and in-centre dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition, surgery products and anaesthetics.
Ramot CEO Shlomo Nimrodi said: “We are gratified to see another one of TAU’s technologies graduating from our unique value enhancement programme the TAU Technology Innovation Momentum Fund.
“We are happy to partner with Baxter to explore how we can bring leading technologies to operating rooms worldwide.”
Founded in 1956, TAU is a research and teaching university, while TASMC is a 1,500-bed academic medical centre affiliated with the university’s medicine faculty.